Effect of Arabinoxylan and Rye Kernels on Second Meal Responses

NCT ID: NCT01583270

Last Updated: 2013-06-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sedentary lifestyles and increasing obesity are main causes of the global increase in the prevalence of the metabolic syndrome (Mets) and type 2 diabetic (T2DM). Diet quality, particularly composition of carbohydrate play also a significant role. Barley, oat and rye may in addition to reducing the acute post prandial glucose response also reduce glucose response at a subsequent meal. Purified dietary fibre has been shown to reduce GI and affect levels of satiety hormones. In contrast, our knowledge of the physiological effect of arabinoxylan, which constitute a substantial part of dietary fibre in cereal products, is limited in relation to second meal effects. The investigators also lack knowledge of the second meal effect of arabinoxyan in combination with rye kernels.

Hypothesis: Porridge rich in arabinoxylan and/or whole rye kernels can increase the formation of short chain fatty acids and improve the glycemic response.

The aim of the present study is to compare the effect of porridge test meals based on purified arabinoxylan, rye kernels, a combination of arabinoxylan and rye kernels, and semolina porridge as control on acute postprandial response as well as response at a subsequent standardized meal. The study will be conducted in subjects with the metabolic syndrome. The primary endpoint is glucose response. Secondary endpoints are the following items: insulin, incretins, inflammatory markers, ghrelin, free fatty acids, metabolomics, breath hydrogen and subjective satiety feeling.

This project will improve opportunities for identifying and designing foods with low GI that is particularly suited to people who are at high risk of developing T2DM. The investigators also expect to gain a greater understanding of the metabolic fingerprint, as seen after ingestion of low-GI foods and thereby gain a molecular understanding of how low-GI foods affect health by altering metabolic processes. This will give us a deeper insight into the metabolic processes that are necessary for maintaining normal glucose homeostasis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Using a cross-over design, 15 subjects with Mets will consume test meals containing four different porridges in randomized order. Blood samples will be collected over 2 hours after ingestion of test meals and 2 hours after ingestion of a standard second lunch meal served 4 hours after the test meals. The amount of porridge and the standard lunch are equivalent to 50 g available carbohydrate. Visual Analog Scale (VAS) will be used for determination of subjective satiety feeling and measurements of breath hydrogen will be used as a marker for colon fermentation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arabinoxylan

Porridge rich in arabinoxylan. 50 g available carbohydrate

Group Type EXPERIMENTAL

Arabinoxylan

Intervention Type DIETARY_SUPPLEMENT

Porridge rich in arabinoxylan

rye kernels

Porridge made from rye kernels. 50 g available carbohydrate

Group Type EXPERIMENTAL

Rye kernel

Intervention Type DIETARY_SUPPLEMENT

Porridge made of rye kernels

arabinoxylan and rye kernels

Porridge made of rye kernels and arabinoxylan. 50g available carbohydrate

Group Type EXPERIMENTAL

Arabinoxylan and rye kernels

Intervention Type DIETARY_SUPPLEMENT

Porridgde made of rye kernels and arabinoxylan

semolina

Semoline porridge. 50 g available carbohydrate

Group Type EXPERIMENTAL

Semolina

Intervention Type DIETARY_SUPPLEMENT

Semoline porridge. control meal.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arabinoxylan

Porridge rich in arabinoxylan

Intervention Type DIETARY_SUPPLEMENT

Rye kernel

Porridge made of rye kernels

Intervention Type DIETARY_SUPPLEMENT

Arabinoxylan and rye kernels

Porridgde made of rye kernels and arabinoxylan

Intervention Type DIETARY_SUPPLEMENT

Semolina

Semoline porridge. control meal.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dietary fibre. Whole grain. Rye. Kernels. dietary fibre. whole grain. rye kernels. Wheat.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Central obesity (Female \> 94 cm; Male \> 80 cm) with two of the following:

1. fasting triglyceride (\> 1,7 mmol/L),
2. HDL-cholesterol: (Female:\< 1,03 mmol/L; Male:\< 1,29 mmol/L),
3. blood pressure (≥ 130/85 mmHg) and
4. fasting plasma glucose (≥ 5,6 mmol/L)). Subjects who are in medical treatment with lipid and blood pressure-lowering drugs can continue with their habitual treatment provided that the treatment is stable throughout the trial.

Exclusion Criteria

* fasting plasma glucose \> 7,0 mmol/l,
* fasting plasma triglyceride \> 5,0 mmol/l,
* blood pressure \> 160/100 mmHg ,
* legal incapacity , endocrine, cardiovascular or kidney disease,
* BMI \> 38kg/m2,
* corticosteroid treatment,
* alcohol or drug addiction and
* pregnancy or lactation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role collaborator

Aarhus University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AnneMarie Kruse

Professor Kjeld Hermansen

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kjeld Hermansen, Professor

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aarhus University Hospital

Aarhus, Aarhus, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2101-08-0068

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

CERN-biofuncarb second meal

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Barley on Glucose Control
NCT02367989 ACTIVE_NOT_RECRUITING NA